BTIG reiterates Monopar Therapeutics stock rating on NDA progress
BTIG reiterated a Buy rating and $133 price target for Monopar Therapeutics (MNPR), citing progress in its NDA submission for ALXN1840. The stock trades at $68.05, with a consensus price target range of $119-$145. Management extended its cash runway guidance to Q1 2028 and presented positive trial data. Analysts have mixed views on the stock's valuation.
How this was made
The 30-second read
Why it matters
Analyst rating and target adjustments provide modest sentiment cues but no new corporate catalyst.
Market read
Minor relevance; primarily an analyst opinion piece.
What to watch
Potential competition and the need for FDA approval could temper upside.
Background
The article repeats analyst coverage of Monopar Therapeutics, focusing on rating and target changes.
Ticker impact
BTIG reiterated a Buy rating and raised the price target to $133, citing progress on the rolling NDA for ALXN1840 and extended cash runway.
likely upward pressure as investors price in the higher target and NDA progress
The rating and target raise are fresh analyst actions, but no new material corporate event; impact is limited to sentiment.
Market effects
Limited; reflects broader biotech analyst sentiment on NDA progress.
None
Low
Counterpoint
The price target may be overly optimistic given the delayed NDA timeline.
Key entities
- CompanyMonopar Therapeutics
Biotech firm developing ALXN1840.
- Analyst FirmBTIG
Issued the reiterated Buy rating and price target.
